Page last updated: 2024-11-07

2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine: cyclic methadone metabolite; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115159
CHEMBL ID196431
CHEBI ID80645
MeSH IDM0056458

Synonyms (12)

Synonym
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
30223-73-5
CHEMBL196431 ,
chebi:80645 ,
FT-0668298
FT-0668297
bdbm50409961
pyrrolidine, 1,5-dimethyl-3,3-diphenyl-2-ethylidene-
1,5-dimethyl-3,3-diphenyl-2 -ethylidene pyrrolidine
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp)
DTXSID10880951
FT-0668299

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Ethylenediamine dinitrate (EDDN) and diethylenetriamine trinitrate (DETN) are relatively insensitive explosive compounds that are being explored as safe alternatives to other more sensitive compounds."( Genotoxicity assessment of ethylenediamine dinitrate (EDDN) and diethylenetriamine trinitrate (DETN).
Johnson, MS; Kirby, P; Reddy, G; Song, J, 2011
)
0.37

Pharmacokinetics

ExcerptReferenceRelevance
" The assay was applied to plasma protein and erythrocyte binding studies and a 96-h pharmacokinetic study in two healthy female volunteers following oral dosing with rac-methadone."( Development and application of a chiral high performance liquid chromatography assay for pharmacokinetic studies of methadone.
Boulton, DW; Devane, CL, 2000
)
0.31
"Eighteen patients recruited from a public methadone maintenance program underwent an interdosing interval pharmacokinetic study."( Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.
Bochner, F; Dyer, KR; Foster, DJ; Somogyi, AA; White, JM, 2000
)
0.31
" Considerable interindividual variability was observed for the pharmacokinetic parameters, with coefficients of variation of up to 70%."( Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.
Bochner, F; Dyer, KR; Foster, DJ; Somogyi, AA; White, JM, 2000
)
0.31
" However, this parameter is usually derived from a small database of human pharmacokinetic studies."( Refining the excretion factors of methadone and codeine for wastewater analysis - Combining data from pharmacokinetic and wastewater studies.
Bruno, R; Hall, W; Lai, FY; Mueller, JF; O'Brien, J; Prichard, J; Thai, PK; van Dyken, E, 2016
)
0.43
" The data suggest that the assay is well suited for pharmacokinetic purposes."( Enantioselective capillary electrophoresis for pharmacokinetic analysis of methadone and 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine in equines anesthetized with ketamine and isoflurane.
Braun, C; Gittel, C; Larenza Menzies, MP; Sandbaumhüter, FA; Theurillat, R; Thormann, W, 2019
)
0.74
" Additionally, the R and S enantiomers of methadone have unique PK and pharmacodynamic properties."( Pharmacokinetic modeling of R and S-Methadone and their metabolites to study the effects of various covariates in post-operative children.
Aruldhas, BW; Gao, H; Heathman, MA; Ly, RC; Masters, AR; Overholser, BR; Packiasabapathy, S; Quinney, SK; Sadhasivam, S, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
"Rectal administration of methadone may be an alternative to intravenous and oral dosing in cancer pain, but the bioavailability of the rectal route is not known."( Bioavailabilities of rectal and oral methadone in healthy subjects.
Dale, O; Kharasch, ED; Sheffels, P, 2004
)
0.32
"Rectal administration of methadone results in rapid absorption, a high bioavailability and long duration of action."( Bioavailabilities of rectal and oral methadone in healthy subjects.
Dale, O; Kharasch, ED; Sheffels, P, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Male long-Evans rats were shaved prior to dosing to obtain their drug-free hair."( Quantitative analysis of methadone and two major metabolites in hair by positive chemical ionization ion trap mass spectrometry.
Foltz, RL; Gygi, SP; Nagasawa, PR; Rollins, DE; Wilkins, DG, 1996
)
0.29
" The assay was applied to plasma protein and erythrocyte binding studies and a 96-h pharmacokinetic study in two healthy female volunteers following oral dosing with rac-methadone."( Development and application of a chiral high performance liquid chromatography assay for pharmacokinetic studies of methadone.
Boulton, DW; Devane, CL, 2000
)
0.31
" MTD excretion was higher in men, decreased with increased urinary pH, and increased with daily dosage of MTD; these factors explain 32% of the total variance of urinary MTD."( Compliance with methadone-based substitutive treatment: a proposed model based on immunoassay urinary sample screening.
Bézie, Y; Billaud, E; Boutouyrie, P; Illier, C; Lillo, A; Prognon, P; Talon, V, 2004
)
0.32
"Rectal administration of methadone may be an alternative to intravenous and oral dosing in cancer pain, but the bioavailability of the rectal route is not known."( Bioavailabilities of rectal and oral methadone in healthy subjects.
Dale, O; Kharasch, ED; Sheffels, P, 2004
)
0.32
" The reason for the large range in dosage may be multifactorial."( Free and bound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment: relationship to dosage?
Eichhorst, JC; Etter, ML; Fern, B; George, S; Graybiel, K; Kapur, B; Lehotay, DC; Selby, P; Wildenboer, W, 2005
)
0.33
" In our current study, we aimed to test the hypothesis that HCV may influence the methadone dosage and its plasma metabolite concentrations in a MMT cohort from Taiwan."( Hepatitis C virus infection influences the S-methadone metabolite plasma concentration.
Chang, YS; Ho, IK; Hsu, YT; Kuo, HW; Liu, SW; Liu, YL; Tsou, HH; Wang, SC; Wu, SL, 2013
)
0.39
" The daily methadone dosage ranged from 10 to 120 mg, mostly as syrup."( Testing for Drugs in Exhaled Breath Collected With ExaBreath in a Drug Dependence Population: Comparison With Data Obtained in Urine After Liquid Chromatographic-Tandem Mass Spectrometric Analyses.
Gaulier, JM; Kintz, P; Mathiaux, F; Villéger, P, 2016
)
0.43
" The knowledge of these important covariates will aid in the optimal dosing of methadone in children."( Pharmacokinetic modeling of R and S-Methadone and their metabolites to study the effects of various covariates in post-operative children.
Aruldhas, BW; Gao, H; Heathman, MA; Ly, RC; Masters, AR; Overholser, BR; Packiasabapathy, S; Quinney, SK; Sadhasivam, S, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)50.11870.00091.901410.0000AID243151
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (123)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.63)18.7374
1990's11 (8.94)18.2507
2000's54 (43.90)29.6817
2010's50 (40.65)24.3611
2020's6 (4.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.20 (24.57)
Research Supply Index4.96 (2.92)
Research Growth Index5.48 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (4.44%)5.53%
Reviews0 (0.00%)6.00%
Case Studies7 (5.19%)4.05%
Observational0 (0.00%)0.25%
Other122 (90.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]